



MEDICATION POLICY

Generic Name: Abiraterone

Therapeutic Class or Brand Name: Zytiga®

Applicable Drugs (if Therapeutic Class): N/A

Date of Origin: 2/1/13

Date Last Reviewed/Revised: 12/13/17

GPI Code: 2140601020

Prior Authorization Criteria (may be considered medically necessary when criteria I through IV are met):

- I. Documented diagnosis of metastatic castration-resistant prostate cancer (mCRPC).
- II. Zytiga® will be used in combination with prednisone.
- III. Minimum age requirement: 18 years old.
- IV. Prescriber is an oncologist or urologist.

Exclusion Criteria:

- Female patients.

Other Criteria:

- N/A

Quantity/Days Supply Restrictions:

- 250 mg strength: 120 tablets per 30 days.
- 500 mg strength: 60 tablets per 30 days.

Approval Length:

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

Appendix:

N/A

References:

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

1. <http://blue.regence.com/trgmedpol/drugs/dru252.pdf>.
2. [Medi-Span](#).
3. <https://www.zytigahcp.com/shared/product/zytiga/zytiga-prescribing-information.pdf>.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

<i>Historical Tracking Of Changes Made To Policy</i>	
12/13/2017	1. Changed “120 tablets per 30 days” to “250 mg strength: 120 tablets per 30 days; 500 mg strength: 60 tablets per 30 days” under Quantity/Days Supply Restrictions.
10/6/2016	1. Updated “ http://www.zytiga.com/sites/default/files/pdf/full_product_information.pdf ” to “ https://www.zytigahcp.com/shared/product/zytiga/zytiga-prescribing-information.pdf ” under References.
4/15/2015	1. Changed “Prescriber is an oncologist” to “Prescriber is an oncologist or urologist” under Prior Authorization Criteria. 2. Changed “N/A” to “Female patients” under Exclusion Criteria.
12/3/2013	1. Adapted policy to new format. 2. Added GPI Code. 3. Updated references to include Medi-Span and updated website address for Zytiga package insert.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.